Novo Nordisk Liraglutide Filing Planned In Q2 2008 For Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
Final Phase III study in LEAD program shows benefit after one year of monotherapy with the once-daily human GLP-1 analogue.